Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Next Science’s (NXS) XPerience no rinse antimicrobial solution has been cleared by the United States Food and Drug Administration (FDA) with sales to start immediately
  • The solution was designed for open surgery cases, giving surgeons a simple and effective aide to help prevent infections
  • The (FDA) has given 510(k) clearance for the solution which marks XPerience as safe and effective, allowing the company to sell the product in the U.S. straight away
  • According to Managing Director Judith Mitchell, the no rinse antimicrobial solution reduces pathogens, which can help eliminate bacteria like golden staph — a major cause of surgical complications and increased morbidity and mortality across the world
  • Shares last traded in the red, down 2 per cent at $1.42

Next Science’s (NXS) XPerience no rinse antimicrobial solution has been cleared by the United States Food and Drug Administration (FDA) with sales to start immediately.

The solution is used post-surgery where the residual solution stays in a surgical site once it’s closed and continues defending against pathogens for several hours.

It was designed for every open surgery case, initially focusing on surgeries of the shoulder, hip, knee as well as trauma and podiatry.

The medical technology company says XPerience No Rinse Antimicrobial Solution gives surgeons a simple and effective aide to help prevent infections.

The U.S. FDA has given 510(k) clearance for the solution, marking it as safe and effective and allowing the company to sell the product in the U.S. straight away.

Next Science’s initial sales focus will be the U.S. orthopaedic surgery market, which the company says provides a market opportunity of over US$1 billion per annum (roughly A$1.3 billion). The potential global market for XPerience is estimated to be greater than US$15 billion (roughly A$19.3 billion) per annum.

According to Managing Director Judith Mitchell, the no rinse antimicrobial solution reduces pathogens, which can help eliminate bacteria like golden staph — a major cause of surgical complications and increased morbidity and mortality across the world.

“XPerience provides an enormous opportunity to help reduce infection, antimicrobial resistance and save lives while reducing expenses for health systems arising from postsurgical infections,” Judith commented.

The company is planning to undertake clinical studies for additional evidence to support widespread implementation of XPerience in the surgical community.

Shares last traded in the red, down 2 per cent at $1.42

NXS by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…